US3984534A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tetrazolyl anthraquinones for inhibiting the release of spasmogen mediators
Assignee: Allen and Hanburys Ltd
•
Filing: 1972-11-29
•
Granted: 1976-10-05
•
Expires: 1992-11-29
Abstract
Abstract Compounds of the general formula: ##SPC1## Wherein X represents a 5-[1H]-tetrazolyl group, R 1 represents a hydrogen atom, a halogen atom, a hydroxyl group or a group --OR 2 , (in which R 2 may be a lower alkyl or alkenyl group containing from 1 to 6 carbon atoms optionally substituted by one or more hydroxy groups, an aryl group, an aryloxy group, an alkoxy group or a dialkylamino group) or a group --NR 3 R 4 , in which R 3 and R 4 which may be the same or different, represent a hydrogen atom, a lower alkyl group containing from 1 to 6 carbon atoms, optionally substituted by a hydroxy group, or R 3 and R 4 together with the nitrogen atom may form a ring which may optionally be substituted with another heteroatom and pharmaceutically acceptable salts thereof. These compounds have useful immunological activity and inhibit the release of spasmogen mediators.
Inventors
- 👤 Mervyn Evan Peel
- 👤 Alexander William Oxford
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 22:23
CPC Classifications
C; C07; C07D; C07D257/00; C07D257/02; C07D257/04
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
82 words
A pharmaceutical composition for inhibiting the release of spasmogen mediators in the antigen-antibody reaction comprising an effective amount of a compound of the formula ##SPC4## wherein: X is 5-[1H]-tetrazolyl, and R 1 is hydrogen or OR 2 , where R 2 is lower alkyl containing up to 6 carbon atoms or lower alkyl containing up to 6 carbon atoms substituted by one or more hydroxy groups; or a pharmaceutically acceptable salt thereof, said compound being in association with a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
82 words
A pharmaceutical composition for inhibiting the release of spasmogen mediators in the antigen-antibody reaction comprising an effective amount of a compound of the formula ##SPC4## wherein: X is 5-[1H]-tetrazolyl, and R 1 is hydrogen or OR 2 , where R 2 is lower alkyl containing up to 6 carbon atoms or lower alkyl containing up to 6 carbon atoms substituted by one or more hydroxy groups; or a pharmaceutically acceptable salt thereof, said compound being in association with a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
10 words
A composition as claimed in claim 1 for oral administration.
Claim 4
Dependent Claim
30 words
A composition as claimed in claim 2 in which the formulation is in the form of dosage unit each dosage unit containing from 5 to 1500 mg of active ingredient.
Claim 5
Dependent Claim
11 words
A composition as claimed in claim 1 for administration by inhalation.
Claim 6
Dependent Claim
30 words
A composition as claimed in claim 4 in the form of an aerosol to be dispensed from an aerosol pack in a metered dose of from 1 to 10 mg.
Claim 7
Dependent Claim
13 words
A composition as claimed in claim 1 in which said compound is 5-[7-(2-hydroxyethoxy)anthraquinone-2-yl]-1H-tetrazole.
Claim 8
Independent Claim
79 words
A method of inhibiting the release of spasmogen mediators in the antigen-antibody reaction in the patient in need thereof which comprises administering an effective amount of the compound of the formula ##SPC5## wherein: X is 5-[1H]-tetrazolyl, and R 1 is hydrogen or OR 2 , where R 2 is lower alkyl containing up to 6 carbon atoms or lower alkyl containing up to 6 carbon atoms substituted by one or more hydroxy groups; or a pharmaceutically acceptable salt thereof.
Claim 9
Independent Claim
79 words
A method of inhibiting the release of spasmogen mediators in the antigen-antibody reaction in the patient in need thereof which comprises administering an effective amount of the compound of the formula ##SPC5## wherein: X is 5-[1H]-tetrazolyl, and R 1 is hydrogen or OR 2 , where R 2 is lower alkyl containing up to 6 carbon atoms or lower alkyl containing up to 6 carbon atoms substituted by one or more hydroxy groups; or a pharmaceutically acceptable salt thereof.
Claim 10
Dependent Claim
15 words
The method of claim 7 wherein said compound is administered in combination with a bronchodilator.
Claim 11
Dependent Claim
10 words
The method of claim 7 wherein said compound is 5-[7-(2-hydroxyethoxy)anthraquinone-2-yl]-1H-tetrazole.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1979-10-05 | 1980-04-05 | 1980-10-05 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1983-10-05 | 1984-04-05 | 1984-10-05 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1987-10-05 | 1988-04-05 | 1988-10-05 | $7700.00 | Window Closed / Lapsed |